# Gain Therapeutics Inc. (GANX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $21M  
**Price:** $1.64 (-0.61%)

> Gain Therapeutics Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics. At the heart of its operations is the proprietary SEE-Tx platform, which enables the identification of previously undruggable targets across a range of diseases, primarily focusing on rare genetic disorders and neurological conditions. By analyzing structural proteins, the company aims to address unmet medical needs in areas such as neurodegenerative diseases, offering potential breakthroughs in treatment options. Gain Therapeutics’ emphasis on protein misfolding disorders underscores its impact on critical therapeutic areas, significantly influencing drug research and development in the biotech sector. The company's efforts contribute to redefining therapeutic approaches, ensuring its relevance and importance in the competitive landscape of medical innovations. Gain Therapeutics, by leveraging cutting-edge technology, positions itself as a transformative entity in the medical field, driving forward advancements in patient care for complex diseases.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2023 | $55,180 | — | -$22M | -$22M | $-1.71 |
| 2022 | $132,640 | — | -$18M | -$18M | $-1.48 |
| 2021 | $133,928 | — | -$14M | -$14M | $-1.37 |
| 2020 | $28,881 | — | -$3M | -$4M | $-1.33 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2023 | $19M | $6M | $13M | $12M | $567,850 |
| 2022 | $24M | $5M | $19M | $7M | $603,393 |
| 2021 | $39M | $4M | $35M | $37M | $694,294 |
| 2020 | $10M | $3M | $6M | $7M | $715,656 |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$18M | — | — |
| 2024 | -$19M | — | — |
| 2023 | -$19M | — | — |
| 2022 | -$15M | — | — |
| 2021 | -$12M | $94,212 | -$12M |
| 2020 | -$3M | $20,826 | -$3M |

Source: [CompaniesByCap](https://companiesbycap.com/company/GANX)